FGAM
NBIX icon

Financial Gravity Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Financial Gravity Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– – – 1849
2023
Q2 		– Sell
-101
Closed -$2.06K – 1734
2023
Q1 		$2.06K Buy
+101
New +$10.5K 0.06% 304
2019
Q3 		– Sell
-3
Closed – – 1432
2019
Q2 		$0 Buy
+3
New +$246 ﹤0.01% 1521

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Financial Gravity Asset Management's NBIX Position: Q1 2024 in Review

Financial Gravity Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q1 2024 at 0 shares worth $40. The position accounts for ﹤0.01% of the portfolio, ranked #1849.

Financial Gravity Asset Management first reported a position in NBIX in Q2 2019 and has held it in 2 quarters since. The position peaked at $2.06K in Q1 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Financial Gravity Asset Management held 0 shares of Neurocrine Biosciences worth $40 as of Q1 2024.
  • Financial Gravity Asset Management left its Neurocrine Biosciences share count unchanged in Q1 2024.
  • Neurocrine Biosciences made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2024, its #1849 holding.
  • Financial Gravity Asset Management first reported a position in Neurocrine Biosciences in Q2 2019 and has held it in 2 quarters since.
  • Financial Gravity Asset Management's Neurocrine Biosciences position peaked at $2.06K in Q1 2023.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Financial Gravity Asset Management's 13F filing for Q1 2024, filed 13 May 2024.